DE69733651D1 - Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung - Google Patents

Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung

Info

Publication number
DE69733651D1
DE69733651D1 DE69733651T DE69733651T DE69733651D1 DE 69733651 D1 DE69733651 D1 DE 69733651D1 DE 69733651 T DE69733651 T DE 69733651T DE 69733651 T DE69733651 T DE 69733651T DE 69733651 D1 DE69733651 D1 DE 69733651D1
Authority
DE
Germany
Prior art keywords
lipid
injections
analogue
production
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69733651T
Other languages
English (en)
Other versions
DE69733651T2 (de
Inventor
Yasuyuki Asai
Katsumi Onai
Kazuhide Ashizawa
Kiyoshi Iwamoto
Yasuo Ishibashi
Sumio Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of DE69733651D1 publication Critical patent/DE69733651D1/de
Application granted granted Critical
Publication of DE69733651T2 publication Critical patent/DE69733651T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69733651T 1996-07-03 1997-07-03 Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung Expired - Lifetime DE69733651T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP17361596 1996-07-03
JP17361596 1996-07-03
PCT/JP1997/002316 WO1998001139A1 (en) 1996-07-03 1997-07-03 Injections containing lipid a analogues and process for the preparation thereof

Publications (2)

Publication Number Publication Date
DE69733651D1 true DE69733651D1 (de) 2005-08-04
DE69733651T2 DE69733651T2 (de) 2006-05-18

Family

ID=15963903

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733651T Expired - Lifetime DE69733651T2 (de) 1996-07-03 1997-07-03 Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung

Country Status (9)

Country Link
US (1) US6235724B1 (de)
EP (1) EP0909562B1 (de)
CN (1) CN1150001C (de)
AT (1) ATE298578T1 (de)
CA (1) CA2259520C (de)
DE (1) DE69733651T2 (de)
DK (1) DK0909562T3 (de)
ES (1) ES2242226T3 (de)
WO (1) WO1998001139A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501540A (ja) * 1997-05-23 2002-01-15 エーザイ株式会社 製薬製剤を調製するための方法
CN1247262C (zh) * 1998-07-14 2006-03-29 惠氏控股有限公司 含有单磷酸脂a的佐剂和疫苗组合物
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
IL151314A0 (en) 2000-02-18 2003-04-10 Eisai Co Ltd Micelles, methods for their preparation and methods for delivery of micelles to patients
PT1889630E (pt) 2000-10-18 2012-02-29 Glaxosmithkline Biolog Sa Vacinas compreendendo o antigénio mage ligado a um fragmento da proteína d
WO2002094019A1 (en) * 2001-05-22 2002-11-28 Eisai Co., Ltd Highly purified antiendotoxin compound
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2486938T3 (pl) 2006-09-26 2018-08-31 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
ES2606563T3 (es) 2009-06-05 2017-03-24 Infectious Disease Research Institute Adyuvantes lipídicos de glucopiranosilo sintéticos y composiciones de vacuna que contienen los mismos
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
AU2011276223C1 (en) 2010-07-06 2016-05-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
EP2663288B1 (de) 2011-01-13 2022-12-21 Variation Biotechnologies Inc. Verfahren zur vesikelherstellung und darin hergestellte formulierungen
EP2694099B1 (de) 2011-04-08 2019-10-16 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2016109880A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216686B (it) * 1988-04-01 1990-03-08 Chiesi Farma Spa Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
JPH04198192A (ja) * 1990-11-28 1992-07-17 Japan Tobacco Inc リピッドａ類縁体の水溶液
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Also Published As

Publication number Publication date
EP0909562A1 (de) 1999-04-21
CA2259520C (en) 2007-09-11
WO1998001139A1 (en) 1998-01-15
CN1150001C (zh) 2004-05-19
DK0909562T3 (da) 2005-08-22
CN1224355A (zh) 1999-07-28
ES2242226T3 (es) 2005-11-01
ATE298578T1 (de) 2005-07-15
CA2259520A1 (en) 1998-01-15
EP0909562B1 (de) 2005-06-29
DE69733651T2 (de) 2006-05-18
US6235724B1 (en) 2001-05-22
EP0909562A4 (de) 1999-12-29

Similar Documents

Publication Publication Date Title
DE69733651D1 (de) Lipid a-analoge enthaltende injektionen und verfahren zu deren herstellung
DE68904986T2 (de) Verfahren zur herstellung von 1,1,1-trifluor-2,2-dichlorethan.
DE68907057T2 (de) Nährstoffzusammensetzung und verfahren zu deren herstellung.
DE69107949D1 (de) MOS-gesteuerter Thyristor und Verfahren zu dessen Herstellung.
ATE187167T1 (de) Amido-3-pyrazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69006290D1 (de) N-Substituierte Benzyloxyiminderivate, Verfahren zu deren Herstellung und deren Verwendung.
ATE334136T1 (de) Verfahren zur herstellung von azithromycin
DE3785163D1 (de) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-en-2-carbonsaeurederivate und verfahren zu deren herstellung.
ATE145649T1 (de) Kardioaktive 17-aryl und 17-heterozyklyl-14 beta- 5alpha-androstane, androstene und androstadiene, ein verfahren zu ihrer herstellung und pharmazeutische präperate davon
DE3862937D1 (de) 3-oxo-propannitril heteroarylderivate und verfahren zu deren herstellung.
DE3777122D1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3872620T2 (de) (arylsulphonyl)-nitromethane, verfahren zu deren herstellung und deren verwendung in pharmazeutischen zusammensetzungen.
DE69012650T2 (de) Piperidinderivat, Verfahren zur Herstellung davon und dieses enthaltende pharmazeutische Zusammensetzung.
DE68910451T2 (de) 1,4-benzoxazin- und 1,4-benzothiazin-derivate und verfahren zu deren herstellung.
ATE121420T1 (de) Verfahren zur herstellung von 3-(l-pyroglutamyl)- l-thiazolidin-4-carbonsäure-derivaten.
DE59001106D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2-chlorethan.
DE3767894D1 (de) 1,2-dithiol-3-thion-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung.
DE3886936T2 (de) 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLEN 2-PGI-DERIVATE, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG.
DE68906500T2 (de) Verfahren zur herstellung von 2,6-dimethylnaphthalin.
DE68923159T2 (de) Verfahren zur Herstellung von 1,4-Dihydropyridin-Derivaten.
DE68917322T2 (de) Motorlagerlegierung und verfahren zu deren herstellung.
DE3869633D1 (de) Verfahren zur herstellung von n,n-(dibenzohexatrienylen)harnstoffen.
DE68907180D1 (de) Verfahren zur herstellung von 2,3,5-trimethylbenzochinon.
DE3861897D1 (de) Verfahren zur herstellung von 4-hydroxy-2,2,6,6-tetramethyl-piperidin.
DE59000677D1 (de) Verfahren zur herstellung von 2-cyan-3,3-diarylacrylsaeureestern.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EISAI R&D MANAGEMENT CO., LTD., TOKYO, JP